Thomas Melissa sold (to issuer) $1.4M of CNK

Thomas Melissa (EVP, Chief Financial Officer) sold (to issuer) 38,236 shares of Cinemark Holdings, Inc. (CNK) at $37.53 ($1.43M total) on 2026-08-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thomas Melissa
Published Aug 20, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CNK
Neutral
medium confidence
Mentioned
$CNK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNKNeutralLow
01

Why it matters

The $1.43 M sale reduces insider ownership but is unlikely to move the stock significantly.

02

Market read

Primary insider sale; modest size; limited trading relevance.

03

What to watch

Potential tax planning or diversification; no indication of operational concerns.

Relevance 5/10Novelty 7/10Timing: today (2026‑08‑20)

Background

Form 4 filings disclose insider transactions; CFO sales are monitored for signals.

Company-level read

Ticker impact

$CNKNeutralMedium confidence
Context

CFO Thomas Melissa sold 38,236 shares for $1.43M via a 10b5‑1 plan, reducing his stake to 129,076 shares.

Expected impact

Potential short‑term downward pressure, but limited impact given modest size.

Evidence & confidence

The transaction is a primary Form 4 filing, $1.4 M is modest for a mid‑cap, and no other catalyst is present.

Market effects

Minimal; entertainment‑theater sector sees no broader impact.

None; the sale is company‑specific.

Low; only relevant to investors in Cinemark.

Counterpoint

The sale could be a routine liquidity move unrelated to outlook.

Key entities

  • Cinemark Holdings, Inc.

    US‑listed theater operator (ticker CNK).

  • Thomas Melissa

    Cinemark CFO and insider.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CNKHigh

Morgan Stanley upgrades Cinemark stock rating on box office outlook

Morgan Stanley upgraded Cinemark (CNK) to Overweight with a $50 price target, citing optimism about 2027 box office growth and the company's strong market position. Cinemark's stock has risen 75.3% year-to-date, trading near its 52-week high. The company reported record Q3 earnings of $1.04 per share on $1.06 billion revenue, exceeding expectations. Other analysts have also raised their price targets following the strong performance.

$CNKHighAI 8/10

StoneX raises Cinemark stock price target on strong quarter

StoneX raised its price target on Cinemark (NYSE:CNK) to $45 from $40, citing strong Q3 results with revenue and adjusted EBITDA exceeding estimates. The firm expects continued growth in 2027, supported by a strong film slate and premium expansion. Cinemark's stock has surged 42% in six months. The company reported record Q3 earnings of $1.04 per share, beating estimates, with revenue reaching $1.06 billion.

$CNKMedAI 8/10

Cinemark stock holds at Neutral as B.Riley keeps $42 target

B.Riley maintained a Neutral rating and $42 price target for Cinemark (CNK) after its Q3 earnings beat estimates. Revenue was $1.059B, EBITDA $268M, driven by Latin America sales. Management is optimistic about future box office growth. Shares are up 65% YTD, trading near a 52-week high. Wells Fargo raised its target to $42, citing international success.

$CNKMed

Cinemark Holdings Inc (CNK) (Q3 2026) Earnings Call Highlights: Record Q3 Revenue

Cinemark Holdings (CNK) reported record Q3 2026 revenue, but faced market share compression due to film mix and capacity constraints. The company expects similar challenges in Q4. Cinemark declined to book Netflix's 'Cliff Booth' on IMAX, citing concerns about the release model. Inflationary pressures and capacity constraints are impacting operations. The company has excess cash and may increase buybacks or dividends. CapEx could rise to invest in new builds and theater enhancements.